Zepbound and Mounjaro are two medications that contain the same active ingredient, tirzepatide, a GLP-1 receptor agonist. The main difference between the two is their approved indications and branding. Mounjaro is FDA-approved for the treatment of type 2 diabetes, while Zepbound is approved for chronic weight management in adults with obesity or excess weight. The two medications have the same mechanism of action and are dosed similarly, but they have different marketing and labeling. Zepbound is specifically designed for weight loss, while Mounjaro is marketed for its ability to help patients with type 2 diabetes lose weight. Some experts believe that the different branding and labeling are intended to allow insurers to deny coverage for Mounjaro for uses other than type 2 diabetes, while Zepbound is specifically designated for weight loss, making it easier for employers to exclude coverage on insurance plans that do not cover weight loss treatment.